LymeBusters
« got an interesting email from George Schwartz... »
Welcome Guest. Please Login or Register. Jul 30, 2010, 6:33pm
We have found that most AOL users are not able to receive their activation code and will need to register with an alternate email address such as Yahoo, GMail, Hotmail, etc.
Joined: Jul 2006 Gender: Male Posts: 1,466 Location: Corona del Mar, CA
got an interesting email from George Schwartz... « Thread Started on Aug 8, 2007, 4:19am »
out of the blue... got mail from Dr. Schwartz in response to something i sent to morgellons_bayarea months ago..
"Microfilaremia is seen on whole blood and is one of the core elements of this disease. Don't argue; don't analyze; Show them slides and scientific data.These are unassailable. Write shorter pieces also. GRS"
(this was in reply to the following -- guess Dr. Schwartz thought he was mailing to James Schaller??: To: morgellons_bayarea@yahoogroups.com Sent: Fri, 30 Mar 2007 22:54:04 -0800 Subject: [morgellons_bayarea] Fwd: Should One Reason with Morgellons’ Cynics? Sample Replies to Their Doubts )
Joined: Jul 2006 Gender: Male Posts: 1,466 Location: Corona del Mar, CA
Re: got an interesting email from George Schwartz. « Reply #1 on Aug 8, 2007, 4:25am »
Yes, since i figure he's sent me mail... maybe he'll read my reply (still drafting). I'm definitely going to ask him a very pressing question regarding his "microfiliarimia" statement:
"Do you still think biltricide is the most effectice drug against morgs, or is ivermectin or moxidectin or fenbendazole or oxybendazole or doramectin or levamisole better?"
Re: got an interesting email from George Schwartz. « Reply #2 on Aug 8, 2007, 8:35am »
Then he'll say: "For $125.00, you can buy my book on the causes of morgellons and how to treat it." Even the people here who went to him for treatment have not been cured. I am not saying the guy is wrong, just don't get you hopes up.
Joined: Mar 2006 Gender: Female Posts: 4,694 Location: Portland, Oregon
Re: got an interesting email from George Schwartz. « Reply #3 on Aug 8, 2007, 9:14am »
Yeah...that $125 book that he asked me to write a chapter for!?! Not floatin' my boat but I told you ! I wonder how that convention went...it he divulged my whole SLF theory like he said he was gonna do!?! Not that he's a bad guy either...he's actually a pretty a'right guy, I've heard conflicting stories, my experience with him was quite pleasant and he was very kind to my children and me. I still owe him a ton of money but hey...I gave him a lot to go on. I hope he is doin' well.
http://lymebusters.proboards39.com/index....6573#1179451814 (another smoking gun... blackfly and oncho... "In other countries, black flies are also carriers of the filarial disease Onchocerciasis, commonly referred to as River Blindness. A blackfly carrying larvae of Onchocerca volvulus bites a victim and transmits the infection. The larvae grow into groups of string-like worms that live wrapped up in a bump under the skin. Adult female worms produce thousands of tiny microfilariae for approximately 8-12 years. Unlike the adults, the microfilariae migrate throughout the victim's skin, causing skin disfigurement and intense itching.") http://lymebusters.proboards39.com/index....6573#1179451537
Onchocerciasis is a major cause of blindness Current strategies rely on mass distribution of ivermectin by a community directed distribution system New chemotherapeutic strategies need to be developed to kill adult worms or sterilise them in the long term Wolbachia symbiotic endobacteria in filarias are essential for fertility and offer novel targets for treatment Anti-wolbachial treatment with 100 mg/day doxycycline for six weeks can be used to treat onchocerciasis Wolbachia have been implicated in the induction of adverse effects of microfilaricidal drugs and may have a role in the development of pathology, including keratitis
Onchocerciasis, or river blindness, caused by the filaria Onchocerca volvulus, affects more than 17 million people in Africa, Latin America, and Yemen. The microfilaricidal agent ivermectin is the principal means of controlling the disease, through mass treatment. Wolbachia endosymbiotic bacteria in filarias have emerged as a new target for treatment with drugs that lead to long term sterilisation of adult female filarias. Participants at recent international meetings have agreed that anti-Wolbachia chemotherapy with doxycycline (currently for six weeks) could be used to treat infected individuals. This approach holds promise for new developments based on registered antibiotics that are affordable in resource poor settings, as extensive registration processes are not needed. Recent experimental findings also indicate that endotoxin-like molecules from Wolbachia have a role in the pathogenesis of the disease and in adverse reactions after treatment.
Also, it is particularly troubling to see the following quote from Gerberding "The morgellons research foundation also clearly states that light and scanning electron microscopy have demonstrated that no worms, nematodes, microfiliaria, insects, or mites have been found"
For one, why the hell is the MRF putting up that kind of misinformation when Dr. Schwartz claims to have identified and isolated various "instars" (developmental stages) of parasites? And why is COMPLETELY UNVERIFIED INFORMATION ON A RANDOM WEBSITE being used by the CDC to decide what an unknown disease is or isn't... aren't they supposed to be doing the studies themselves, as opposed to using non-peer-reviewed information taken from the internet??
View Previous Record View Next Record Assessment of microfilarial loads in the skin of onchocerciasis patients after treatment with different regimens of doxycycline plus ivermectin Debrah A.Y., Mand S., Marfo-Debrekyei Y., Larbi J., Adjei O. and Hoerauf A. Filaria Journal 2006 5:- (10p)
Other works by authors of this record Debrah A.Y., Mand S., Marfo-Debrekyei Y., Larbi J., Adjei O., Hoerauf A.
EMTREE drug index terms Where this term is the major focus: doxycycline (adverse drug reaction), doxycycline (drug combination), doxycycline (drug comparison), doxycycline (drug dose), doxycycline (drug therapy), ivermectin (adverse drug reaction), ivermectin (drug combination), ivermectin (drug comparison), ivermectin (drug dose), ivermectin (drug therapy)
EMTREE medical index terms Where this term is the major focus: Microfilaria, onchocerciasis (drug therapy), onchocerciasis (etiology) Where this term is mentioned: Ghana, adult, article, controlled study, diarrhea (side effect), disease severity, drug dose regimen, drug efficacy, drug tolerability, fever (side effect), follow up, headache (side effect), hematochezia (side effect), human cell, human tissue, human, infection control, lymphadenitis (side effect), major clinical study, outcomes research, parasite identification, patient care, pruritus (side effect), rash (side effect), skin biopsy, swelling (side effect)
Author Address A. Hoerauf. Institute for Medical Parasitology, University of Bonn, Sigmund-Freud-Str. 25, D-53105 Bonn, Germany.
Author E-mail hoerauf@parasit.meb.uni-bonn.de
Copyright Copyright 2006 Elsevier B.V., All rights reserved.
Quote:
Lethal LPS-independent side effects after microfilaricidal treatment in Acanthocheilonema viteae-infected rodents Müller H.A. and Zahner H. Parasitology Research 2005 97:3 (201-208)
Other works by authors of this record Müller H.A., Zahner H.
EMTREE drug index terms Where this term is the major focus: diethylcarbamazine (drug therapy), diethylcarbamazine (drug toxicity), diethylcarbamazine (oral drug administration), levamisole (drug therapy), levamisole (drug toxicity), levamisole (oral drug administration), lipopolysaccharide Where this term is mentioned: n(g) methylarginine (drug therapy), n(g) methylarginine (intraperitoneal drug administration)
EMTREE medical index terms Where this term is the major focus: Microfilaria, acanthocheilonema viteae, lethality, microfilariasis (drug resistance), microfilariasis (drug therapy), microfilariasis (etiology) Where this term is mentioned: Brugia malayi, Litomosoides carinii, Mastomys coucha, Mastomys, Wolbachia, acidosis, animal experiment, animal model, article, blood, body temperature, controlled study, density, desensitization, drug efficacy, drug fatality, drug tolerability, endosymbiont, genus, hematocrit, homogenate, hypersensitivity, mortality, nonhuman, priority journal, provocation test, rat, treatment outcome
Author Address H. Zahner. Institute for Parasitology, Justus Liebig University Giessen, Rudolf-Buchheim-Straße 2, 35392 Giessen, Germany.
Author E-mail horst.zahner@vetmed.uni-giessen.de
Copyright Copyright 2005 Elsevier B.V., All rights reserved.
Quote:
Endosymbiotic Wolbachia of parasitic filarial nematodes as drug targets Rao R.U. Indian Journal of Medical Research 2005 122:3 (199-204)
Related articles
The parasitic nematodes Wuchereria bancrofti, Brugia malayi and B. timori cause a dreadful disease in humans known as lymphatic filariasis, which afflicts more than 120 million people worldwide. As per recent epidemiologic estimates on prevalence of W. bancrofti and B. malayi, about 428 million people are at risk, with 28 million microfilaria carriers and 21 million clinical cases spread out in 13 States and 5 Union Territories of India. The Indian subcontinent that comprises Bangladesh, India, Maldives, Nepal and Sri Lanka harbours 50 per cent of the world's lymphatic filarial disease burden. Recently, an endobacterium of Wolbachia species that belongs to the family Rickettsiaceae was found in all life cycle stages of these nematodes and the transmission is exclusively vertical through the embryonic stages of the female worms. People with filariasis have been exposed to these Wolbachia bacteria or their proteins by the natural killing of parasites. Wolbachia have also been identified occasionally in body fluids of infected patients. Evidence suggests that these Wolbachia are mutualistic symbionts and can be cured from the nematodes by several antibiotics having antirickettsial properties. Treatment of nematodes with tetracyclines affect Wolbachia and they get cleared from worm tissues; and this elimination causes reproductive abnormalities in worms and affect worm's embryogenesis, resulting in sterility. Although it is impractical, prolonged treatment with doxycycline significantly reduces the numbers of microfilaria in circulation, which is an important strategy to control transmission of filariasis by mosquito vectors. In this review, the current knowledge of Wolbachia as a drug target and potential ways to reduce the infection through anti-Wolbachia treatments is discussed.
EMTREE medical index terms Where this term is the major focus: Wolbachia, filariasis (drug therapy), lymphatic system infection (drug therapy) Where this term is mentioned: Bangladesh, Brugia malayi, Brugia, India, Maldives, Microfilaria, Nepal, Rickettsiaceae, Sri Lanka, Wuchereria bancrofti, bacterium identification, body fluid, clinical trial, developmental stage, disease transmission, drug bioavailability, drug delivery system, drug efficacy, drug mechanism, drug targeting, embryo development, endosymbiosis, eye injury (side effect), human, infection risk, life cycle, nematodiasis (drug therapy), nonhuman, onchocerciasis (drug therapy), parasite vector, parasitosis (drug therapy), prevalence, review, side effect (side effect), species, vertical transmission
Author Address R.U. Rao. Department of Internal Medicine, Infectious Diseases Division, Washington University School of Medicine, 660 S Euclid Ave., St. Louis, MO 63110, United States.
Author E-mail rrao@wustl.edu
Copyright Copyright 2005 Elsevier B.V., All rights reserved.
Joined: Jul 2006 Gender: Male Posts: 604 Location: Corona del Mar, CA
Re: CDC for Jan 07 report-lots of similarities her « Reply #6 on Dec 27, 2006, 8:01am » [Quote] [Modify] [Delete] Well, I'm trying this approach: "In particular, given that tetracycline affects all stages of embryonic development, it might have pharmacologic effects complementary to ivermectin, whose effects are confined to the late stage of microfilarial development, the stretched microfilariae (3), and which does not kill the endobacteria in microfilariae of O. volvulus (37). The endosymbiotic bacteria of filariae, and their potential as a target in treatment of human and animal disease, merit renewed attention." (see http://lymebusters.proboards39.com/index....ge=2#1162019732 )
"I've been on ivomect for 8 years" so discourageing to hear those phrases,,so long to be on the meds without a cure so if after 8n years, why continue?,as horse paste is the only thing in my case that comes any where near knocking it down and that is only topical to date.. I figured that I had a chance if I could get some inside of me. The fenben that I took (walmart) back in Aug sure took care of the black worms (filariosis) nematode...I need to do another round of it soon.
In articles about human filiarisis... i've seen mention of people needing to be on drugs like ivermectin for 10 years -- the entire life-span of the adult parasite -- in order to achieve "cure". The same article goes on to indicate that other drugs, like moxidectin and probably others too (doramectin? levamisole?) may eradicate more stages of parasite. Ivermectin is a "microfiliaricide" and what is needed is a "macrofiliaricide" like moxidectin.
see the last part that talks of "pharmacologic effects [of tetracycline] complementary to ivermectin, whose effects are confined to the late stage of microfilarial development, the stretched microfilariae (3), and which does not kill the endobacteria in microfilariae of O. volvulus (37)" -------------- To apply tetracycline as a supportive therapy to improve antifilarial treatment to humans, it will have to influence the parasite load not only when applied from the beginning of infection, before symptoms occur, but also when applied after the onset of patency, the stage at which the infection is usually diagnosed (36). In this context, it is of importance that tetracycline, when administered to animals harboring already established infections, still dramatically reduced microfilaremia (Fig. 4) and adversely affected female[nematode/filiaria] fertility. This could be a direct microfilaricidal effect or could result from a disruption of microfilarial production at the level of embryogenesis. [...] The macrofilaricidal and antimicrofilaremia effect of tetracycline during patency suggests that a similar approach might be useful for treatment of human filarial diseases. In particular, given that tetracycline affects all stages of embryonic development, it might have pharmacologic effects complementary to ivermectin, whose effects are confined to the late stage of microfilarial development, the stretched microfilariae (3), and which does not kill the endobacteria in microfilariae of O. volvulus (37). The endosymbiotic bacteria of filariae, and their potential as a target in treatment of human and animal disease, merit renewed attention. ----------
Achim Hoerauf,1 Kerstin Nissen-Pähle,1 Christel Schmetz,1 Kim Henkle-Dührsen,1 Mark L. Blaxter,2 Dietrich W. Büttner,1 Michaela Y. Gallin,1 Khaled M. Al-Qaoud,1 Richard Lucius,3 and Bernhard Fleischer1 1Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany2Institute of Cell, Animal and Population Biology, University of Edinburgh, Edinburgh E H9 3DT, United Kingdom3Lehrstuhl für Molekulare Parasitologie, Humboldt-Universität, 10115 Berlin, Germany
Address correspondence to: Achim Hoerauf, Bernhard Nocht Institute for Tropical Medicine, Bernhard-Nocht-Strasse 74, 20359 Hamburg, Germany. Phone: 49-40-31182-495; Fax: 49-40-31182-400; E-mail: hoerauf@bni.uni-hamburg.de
Received August 1, 1998; Accepted October 22, 1998.
Abstract
Intracellular bacteria have been described in several species of filarial nematodes, but their relationships with, and effects on, their nematode hosts have not previously been elucidated. In this study, intracellular bacteria were observed in tissues of the rodent parasite Litomosoides sigmodontis by transmission electron microscopy and by immunohistochemistry using antiendobacterial heat shock protein-60 antisera. Molecular phylogenetic analysis of the bacterial 16S ribosomal RNA gene, isolated by PCR, showed a close relationship to the rickettsial Wolbachia endobacteria of arthropods and to other filarial intracellular bacteria. The impact of tetracycline therapy of infected rodents on L. sigmodontis development was analyzed in order to understand the role(s) these bacteria might play in filarial biology. Tetracycline therapy, when initiated with L. sigmodontis infection, eliminated the bacteria and resulted in filarial growth retardation and infertility. If initiated after microfilarial development, treatment reduced filarial fertility. Treatment with antibiotics not affecting rickettsial bacteria did not inhibit filarial development. Acanthocheilonema viteae filariae were shown to lack intracellular bacteria and to be insensitive to tetracycline. These results suggest a mutualistic interaction between the intracellular bacteria and the filarial nematode. Investigation of such a mutualism in endobacteria-containing human filariae is warranted for a potential chemotherapeutic exploitation.
New and Improved Tools TDR Fifteenth Programme Report
NEW CANDIDATES IN DEVELOPMENT
Drug development: ONCHOCERCIASIS and LYMPHATIC FILARIASIS
Studies are ongoing on the use of albendazole in combination with ivermectin, DEC or levamisole for the treatment of onchocerciasis, lymphatic filariasis and geohelminths, while trials in animals have shown moxidectin to be a potential macrofilaricide
Two types of drug are described for treatment of onchocerciasis and lymphatic filariasis:
* microfilaricides, which kill immature worms
* macrofilaricides, which kill adult worms.
Existing microfilaricides are effective, but there is no suitable macrofilaricide currently available. Because treatment with microfilaricides must be maintained for a number of years, in fact for the length of life of the adult worm in the human host (more than 10 years in the case of onchocerciasis), a suitable, safe and effective macrofilaricide would allow more impact to be made on controlling filarial diseases than is currently possible using microfilaricidal treatment.
Albendazole combinations Levamisol trial in Ghana Levamisol trial in Ghana
TDR, through its network of clinical researchers, is supporting studies to evaluate albendazole in combination with either ivermectin or levamisole as potential macrofilaricidal treatment for O. volvulus patients, and albendazole co-administered with either ivermectin or diethylcarbamazine (DEC) for treatment of lymphatic filariasis patients.
The studies in onchocerciasis patients are being conducted at the Onchocerciasis Clinical Research Center in Hohoe, Ghana. The effects of single-dose co-administration of ivermectin (Mectizan) with albendazole, of albendazole with levamisole, or of ivermectin with levamisole, are being evaluated, the primary end points being safety, pharmacokinetics and effect on microfilaria and macrofilaria. Preliminary results suggest that, although safe, none of the combinations is more effective on adult worms than ivermectin alone. Also, so far, no pharmacokinetic drug interactions have been detected.
partnersThe studies in lymphatic filariasis patients are being conducted in light of the WHO/SmithKlineBeecham (now GlaxoSmithKline) / Merck recommendations on use of co-administration of albendazole with ivermectin or DEC for elimination of lymphatic filariasis. Three studies are in progress:
1. On the Island of Pemba, Tanzania, a randomized, double blind study in 1000 subjects is under way to compare single-dose ivermectin + albendazole with single-dose ivermectin alone. This study will define:
a) unacceptable adverse drug reactions occurring within 7 days of treatment
b) the proportion of microfilaria positive subjects that, one year after treatment, remain microfilaria negative – the primary endpoints being 80% reduction in prevalence for ivermectin alone and 90% reduction in prevalence for albendazole + ivermectin.
As secondary end-points, the study will assess:
a) prevalence of microfilaremic subjects 3 and 6 months after treatment, and reduction in microfilaremia 3 and 6 months after treatment
b) the cure rate (proportion of patients with clearance of eggs from stools) of Trichuris trichiura (human whipworm) infections 21 days after treatment, and reduction in the T. trichiura egg count 21 days after treatment compared to before treatment
c) cure of other soil transmitted helminths.
The results are expected during the 3rd quarter 2002.
2. In Alleppey, India, a study in lymphatic filariasis infected vs. uninfected individuals is under way to evaluate the pharmackokinetic profiles of albendazole and DEC when administered as single drugs or when co-administered as in lymphatic filariasis elimination programmes. Besides assessing safety and laboratory parameters, this study will, for the first time, determine if there is any adverse pharmacokinetic drug interaction. Determination of drug plasma levels will be carried out at the University of Iowa, US. Results of the study are expected to be available during the 4th quarter of 2001.
3. In Wardha, India, a study in 1347 subjects is ongoing to assess the safety, tolerability, efficacy and population pharmacokinetics of DEC co-administered with albendazole as compared to DEC administered alone. The primary end-points will be information on the number of patients without microfilaraemia at 3, 6 and 12 months after treatment, and on the clinical signs and symptoms and adverse events in the two arms of the study. The results are expected to be available during the 4th quarter 2002.
> A suitable macrofilaricide? > > A drug that is used in veterinary medicine > has been shown to have interesting > macrofilaricidal activity in animal models of > onchocerciasis and lymphatic filariasis, and > is now ready for evaluation in humans. > Final results of moxidectin trials in animal > models were presented to the TDR Product > Research and Development Committee in > March 2000. These preclinical studies have > shown that the compound fulfils the criteria > for a potential macrofilaricide (i.e. a drug > that kills adult filarial worms) and has unique > ‘selling points’: > ** a single treatment produces ‘slow’ death > of adult worms in girds and dogs, and sterilization > of worms in cattle. > ** compared to ivermectin (a microfilaricide, > which kills larval stages of filarial > worms), moxidectin has a considerably > longer half life in plasma - 20 days compared > to 2 days - allowing for the possibility > of either less frequent treatment, or > ‘higher efficacy’ with similar frequency of > treatment, compared to ivermectin. > ** it is effective in animal helminth infections > that are resistant to ivermectin. > Moxidectin is a fermentation product from > Streptomyces cyaneogriseus spp noncyanogenus. > Chemically it is related to other > A suitable macrofilaricide? > nematocides – the avermectins – but instead > of a disaccharide side chain it has > unique methoxine- and dimethylbutenylside > chains. > A suitable, safe and effective macrofilaricide > would allow more impact to be made on > controlling filarial diseases than is currently > possible using microfilaricides, even though > the latter are effective. This is because adult > worms can survive in the human host for a > number of years (more than 10 in the case > of onchocerciasis) and treatment with > microfilaricides has to be maintained for the > lifetime of the adult worm. > Currently moxidectin is only available in > veterinary formulations, but discussions are > under way with the company that produces > them to obtain material for humans use. As > soon as clinical grade moxidectin becomes > available, clinical trials will start. > WHO/TDR/Ottesen > Adult filarial worm: the long search for a useful macrofilaricide may soon be over?
p13: ----- > Since the early 1990s, evidence has been > accumulating for the prophylactic effects > of the artemisinins (artesunate, artemether) > against Schistosoma japonicum infections. > 1 In addition to their well-known effect > against the malaria parasite, these drugs > also kill juvenile forms (schistosomula) of > schistosomes: artemisinins have now been > shown to be effective against S. mansoni > in animals and humans,2 ,3 ,4 while laboratory > work on S. haematobium has been > completed and field studies are under way, > with support from TDR. Since these schistosome > species are responsible for the majority > of infections worldwide, and are the > predominant species in Africa, the outcome > could be a major impact on control of schistosomiasis > worldwide. > In a study on the use of artemether in S. mansoni > infections in hamsters and mice, very > few animals developed schistosomiasis when > treated during the fi rst month after infection. > The parasite was particularly susceptible > between weeks 3 and 4 after infection.3 Single > treatment with artemether gave cure rates > of up to 82%, but multiple therapy raised this > to almost 100% in all cases. In animals with > repeated infection, representing more > closely the real situation in nature, there > was almost complete protection. Previous > studies using S. mansoni had shown no effect > of artemether, but had concentrated on > the adult parasite, not the schistosomula. A > clinical trial in Côte d’Ivoire has confirmed > this potential of artemether to significantly > reduce S. mansoni infection.4 > Artemether is already in use as an antimalarial > and has a good safety profile. > Praziquantel is a drug that has been used > for schistosomiasis for more than two decades. > It also is safe and effective, but has to > be given repeatedly due to rapid reinfection. > Combined treatment with the two drugs > has been studied in rabbits infected with S. > japonicum parasites at different developmental > stages (young stages and adults), > representing the natural situation in areas > where infection occurs throughout the year. > Using this animal model, combined treatment > with the two drugs significantly increased > the effects of the individual drugs.5 > Praziquantel and artemether affect > schistosomes at different developmental > stages, and work surprisingly well together > in this respect. Praziquantel affects the adult > parasites, but also the very young stage (realistically > only during the first day in the host) > - the very times at which artemether has no > effect. Conversely, artemether affects the juvenile > stages (except immediately after infec- > Artemether protects against schistosome > infection > tion), thereby blocking the development of > the adult stages. Whether the two drugs can > actually be given simultaneously - whether > there is any pharmacological interaction - remains > to be investigated. Since artemether > blocks the development of adult worms, even > a limited period of treatment with this drug > could theoretically wipe out parasite transmission > in certain areas. Praziquantel on the > other hand, cannot stop the infection, but > remains the cornerstone of control since it > retards the development of morbidity. > The different species of parasite are sensitive > to artemether for slightly different > lengths of time. S. japonicum is susceptible > up to 21 days of age, while S. mansoni > responds to the drug for up to 42 days, and > S. haematobium, due to the longer time it > takes to develop into the adult, has an even > longer period of sensitivity. > In areas that are endemic for both malaria > and schistosomiasis, the use of artemether > is precluded because of the possibility that > its regular use might contribute to the development > of resistance of the malaria parasite. > On the other hand, the drug could > safely be recommended for use in schistosomiasis > in areas where there is no regular > malaria transmission (e.g. in China, southern > Brazil, countries north of the Sahara, > parts of the Middle East). Of particular interest > are those areas where human schistosomiasis > has been very much reduced, > but final eradication has proved difficult > (e.g. in Saudi Arabia, Morocco), where > artemether could contribute to breaking its > transmission; it could also play an important > role in the control of schistosomiasis > in Egypt. > 1 Southeast Asian J Trop Med Public > Health, 1995, 26: 306-308 > 2 Trans R Soc Trop Med Hyg, 2000, 94: 90-91 > 3 Parasitology International, 2000, 49: 19-24 > 4 Lancet, 2000, 355: 1320-1325 > 5 Parasitology International, 2000, 49: 25-30
----------------------
and on p. 3... something about artemesin used for malaria treatment...
Joined: Jul 2006 Gender: Male Posts: 1,466 Location: Corona del Mar, CA
Re: got an interesting email from George Schwartz. « Reply #7 on Aug 25, 2007, 5:39pm »
After much persuasion, the showing of Dr Schwartz letter and my LLMD's "presumptive diagnosis" Kaiser infectious disease is now going to test me for microfiliaria with a "blood smear" and microscopic examination.
Specimen: 2 x 10 ml Lavender top tubes (EDTA) collected at noon and 2 x 10 ml Lavender top tubes collected at midnight (more may be necessary for light infections). Microbiology (#11854) 24 hours (speciation will take longer) Reference Range: No parasites found Result: Specimen: Inpatient Req: Microfilaria, blood smear examination Outpatient Req: Clinical Labs (#83608) Lab: Microbiology (Parasitology) NOTE: Please note patient's travel history on requisition. Blood drawn at midnight should be refrigerated until morning and sent to lab. If only one microfiliaria is in question, (Brugia, Loa loa, Wuchereria), call lab for optimal blood collection time. Diethylcarbamazine stimulation test may be useful.
Microfiliaria Smear Includes: Concentration, stain and examination of blood, for microfilaria speciation. Lab and Phone #: Parasitology, (608) 262-6386 Specimen and Volume: 2 ml of blood in EDTA as an anticoagulant. Container: Vacutainer tube with EDTA Forms Required: CDD Requisition Form (A). Collection: Venous blood; time of collection varies with species suspected. Normal Range: No microfilaria found Availability: Monday - Friday Turnaround Time: Same day Use of Test: To diagnose cases of filariasis. Test Code: 675
Joined: Jul 2006 Gender: Male Posts: 1,466 Location: Corona del Mar, CA
Re: got an interesting email from George Schwartz. « Reply #8 on Aug 25, 2007, 5:42pm »
one of the interesting things about the test is that it should be done at night due to "nighttime activity of filiaria" which apparently peaks between 10PM and 2AM... so I'm getting my blood draw done at a lab (Kaiser's Lakewood Facility/Hospital in Anaheim which closes at 10PM.... Ah Kaiser Lakewood, the anti-disneyland of medicine where every childs dream turns into a nightmare.
Joined: Jul 2006 Gender: Male Posts: 1,466 Location: Corona del Mar, CA
Re: got an interesting email from George Schwartz. « Reply #9 on Aug 25, 2007, 5:50pm »
Just as I suspected, the microfilaria test Kaiser will perform on me will miss Oncho, which I've already mentioned is a strong "smoking gun" behind the parasitic part of morgellons and has apparently been seen in Morg-centric places in the United States, such as Los Angeles (see http://lymebusters.proboards39.com/index....ge=1#1179451537 ).
Joined: Jul 2006 Gender: Male Posts: 1,466 Location: Corona del Mar, CA
Re: got an interesting email from George Schwartz. « Reply #10 on Aug 25, 2007, 5:57pm »
What's the "leopard rash" look like anyway??
Quote:
Bug: Onchocerca volvulus Transmission: Humans, bite by black flies, rivers in tropical Africa and Central America Clinical Features: Onchocerciasis ("leopard" rash cause by hypersensitivity reaction to microfilariae); River blindness (microfilariae induces inflammation in eye leads to scarring and blindness) Diagnosis: Skin biopsy, slit lamp visualization of microfilariae in eye; eosinophilia Tx: Ivermectin (microfilariae), suramin (adult worms)
Joined: Jul 2006 Gender: Male Posts: 1,466 Location: Corona del Mar, CA
Re: got an interesting email from George Schwartz. « Reply #13 on Aug 25, 2007, 6:19pm »
Looks like pets have a good medicine that we don't:
Quote:
Advocate is a combination of moxidectin and imidacloprid in a solution containing 2.5% moxidectin and 10% imidacloprid for dogs, and 1.0% moxidectin and 10% imidacloprid for cats. It is designed for dermal application for the prevention and/or control of a range of internal and external parasites in dogs and cats.
Basically, it's topical moxidectin combined with the flea-killer they use in "advantage"
Quote:
Imidacloprid History Imidacloprid was the first commercialized member of a new class of insecticides called chloronicotinyl nitroguanidines or neonicotinoids. First synthesized in its active form by Bayer in Japan in 1986, it was developed for control of a variety of insects for both agricultural and veterinary purposes
Anybody try putting "advantage" on their lesions?? I've already tried Moxidectin and pretty effective topically. (So damn expensive to use that way though).
The right to do something does not necessarily mean that doing it is always right.
Joined: Nov 2004 Gender: Female Posts: 1,634
Re: got an interesting email from George Schwartz. « Reply #14 on Aug 25, 2007, 7:14pm »
Quote:
Hanging groin (HG) involves the folds of inelastic, atrophic skin in the inguinal areas. The condition may be unilateral or bilateral, and it may involve enlarged lymph nodes.
In Africa, the nodules are often observed along the iliac crests, ribs, greater trochanters, and ischial tuberosities. Juxta-articular areas, such as the knees, elbows, patella, and scalp, may also have nodules.
In the American forms, nodules are fewer and have a greater tendency to be located on the scalp. In patients with scalp nodules, the risk of ocular complications is generally higher than that of patients without scalp nodules.
Onchocercal dermatitis is the most common symptom of the disease.
Its initial manifestations, which can occur anywhere on the body, include itching, scratching, and alterations in skin pigmentation.
Pruritus may be intermittent and mild, continuous and severe, or absent.
A maculopapular rash may appear anywhere on the body at any time.
The papules may be small and densely packed or large and separated.
The maculopapular rash is often associated with severe pruritus. Excess scratching may lead to bleeding, ulceration, and secondary infection (a condition West Africans call craw-craw).
Leopard skin involves depigmentation of the pretibial areas of the lower extremities. This pattern is initially seen as discrete depigmented macules, with sparing of the hair follicles.
Later, the macules may become confluent, involving a large area of the anterior portion below the knee.
HG or adenolymphocele is a severe degenerative condition in older individuals.
The inguinal and femoral lymph nodes become progressively enlarged and fibrotic, leading to lymphatic obstruction.
Concomitantly, progressive destruction of elastic fibers leaves the skin thinned and wrinkled.
The atrophied skin tends to hang in apronlike folds under the weight of the accumulating lymphedematous tissue.
Many of us have been diagnosed with myasis and this explains a lot of our symptoms perfectly. Much of it is also similar to ACA, which Dr. H thinks is connected to European Borrellia infections.
The paper-thin areas move about the skin and you can get a rash just from passing your thumb over the area. Adding slight pressure will often break the skin and I think that starts some of the open sores many experience. Often just the simple act of carrying a lightweight plastic bag around my wrist for a few seconds will bring about this rash and occasional skin rupture.
I have the atrophy and macules in areas where there is no fat, like the elbows and knees. The wrinkles started around my ankles many years ago and move about, lessening in some areas and worsening in others.
A lot of us may have different things going on but the (possible cause and) effect of what is under our skin remains the same.
Re: got an interesting email from George Schwartz. « Reply #15 on Aug 25, 2007, 9:53pm »
The first place my little dog got his lesion with black pepper specks spilling out 24/7 was on the area between his shoulders where I always applied the Advantage.
I wouldn't put that on my skin for fear the same thing would happen to me. It is in essence, a pesticide, and I think it contributed or, possibly, caused his morgs. The morgs went straight to the most vulnerable spot on his body.
After that experience, I truly believe those products are dangerous.
![[Home]](http://images.proboards.com/new/menu/home.png "[Home]")
![[Help]](http://images.proboards.com/new/menu/help.png "[Help]")
![[Search]](http://images.proboards.com/new/menu/search.png "[Search]")
![[Login]](http://images.proboards.com/new/menu/login.png "[Login]")
![[Register]](http://images.proboards.com/new/menu/register.png "[Register]")
![[Live Chat]](http://images.proboards.com/new/menu/chat.png "[Live Chat]")
![[Search This Thread]](http://images.proboards.com/new/buttons/search2.png "[Search This Thread]")
![[Send Topic To Friend]](http://images.proboards.com/new/buttons/sendtopic.png "[Send Topic To Friend]")
![[Print]](http://images.proboards.com/new/buttons/print.png "[Print]")
Author
![[avatar]](http://morgellonswiki.info/img/090226-psychedelic-fish-picture_big-ap.jpg "[avatar]")
![[homepage]](http://images.proboards.com/new/buttons/www_sm.png "[homepage]")
Logged![[image]](http://www.devcan.com/imagehost/uploads/a5e44c9d5a.jpg "[image]")
! I wonder how that convention went...it he divulged my whole SLF theory like he said he was gonna do!?! Not that he's a bad guy either...he's actually a pretty a'right guy, I've heard conflicting stories, my experience with him was quite pleasant and he was very kind to my children and me. I still owe him a ton of money but hey...I gave him a lot to go on. I hope he is doin' well.
![[image]](http://www.emedicine.com/derm/images/1400LEOPARD.JPG "[image]")
![[image]](http://www.devcan.Com/imagehost/uploads/d0cb175a93.jpg "[image]")
![[avatar]](http://i124.photobucket.com/albums/p3/psichik/dobbsgray3x45.gif "[avatar]")
![[avatar]](http://s1.simpload.com/090246db024e6bd15.gif "[avatar]")
![[image]](http://s1.simpload.com/10194719379381a9c.jpg "[image]")